(0.08%) 5 521.25 points
(0.14%) 39 898 points
(0.16%) 19 783 points
(-0.09%) $81.56
(0.68%) $2.83
(-0.26%) $2 338.20
(0.10%) $29.56
(0.48%) $1 006.60
(0.06%) $0.932
(-0.02%) $10.53
(0.02%) $0.788
(-0.85%) $87.25
1.27% $ 1.600
Live Chart Being Loaded With Signals
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders...
Stats | |
---|---|
Dzisiejszy wolumen | 58 863 |
Średni wolumen | 190 485 |
Kapitalizacja rynkowa | 41.48M |
EPS | $-0.290 ( Q1 | 2024-03-31 ) |
Następna data zysków | ( $-0.290 ) 2024-08-09 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-3.40 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.00800 (0.50%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-06-11 | Rodgers Richard J | Buy | 41 143 | Common Stock |
2024-06-11 | Rodgers Richard J | Buy | 35 181 | Stock Option (Right to Buy) |
2024-06-11 | Pepose Jay | Buy | 41 143 | Common Stock |
2024-06-11 | Pepose Jay | Buy | 35 181 | Stock Option (Right to Buy) |
2024-06-11 | Manuso James S J | Buy | 41 143 | Common Stock |
INSIDER POWER |
---|
96.19 |
Last 94 transactions |
Buy: 4 001 388 | Sell: 115 125 |
Wolumen Korelacja
Ocuphire Pharma, Inc. Korelacja
10 Najbardziej pozytywne korelacje |
---|
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Ocuphire Pharma, Inc. Korelacja - Waluta/Towar
Ocuphire Pharma, Inc. Finanse
Annual | 2023 |
Przychody: | $19.05M |
Zysk brutto: | $19.04M (99.97 %) |
EPS: | $-0.460 |
FY | 2023 |
Przychody: | $19.05M |
Zysk brutto: | $19.04M (99.97 %) |
EPS: | $-0.460 |
FY | 2022 |
Przychody: | $39.85M |
Zysk brutto: | $39.85M (99.99 %) |
EPS: | $0.900 |
FY | 2021 |
Przychody: | $589 000 |
Zysk brutto: | $0.00 (0.00 %) |
EPS: | $-3.82 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Ocuphire Pharma, Inc.
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and diabetic macular edema; and APX2009 and APX2014 second generation preclinical product candidates and analogs of APX3330. Ocuphire Pharma, Inc. is headquartered in Farmington Hills, Michigan.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej